- CEO
- William Rosellini
- Full Time Employees
- 62
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1910 Pacific Avenue Dallas TX United States of America 75201
- IPO Date
- Sep 27, 2017
- Business
- Nexeon MedSystems Inc. (NXNN) develops, manufactures and commercializes neurostimulation technology platforms for treating neurological disorders through electrical stimulation of neural tissues; its core offerings include deep brain stimulation systems such as the Viant for Parkinson's disease in the United States and for Parkinson's disease, essential tremor and dystonia in Europe, alongside technologies spanning peripheral nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation and advanced depth electrodes for epilepsy monitoring and neural interfaces. Founded in 2005 and headquartered in Dallas, Texas, with manufacturing and clinical subsidiaries in Belgium, the company operates globally in the bioelectronics and medtech sectors, targeting patients with debilitating conditions like migraines, cardiovascular disease and sepsis via implantable devices and IoT-enabled remote management software. Recent developments encompass a November 2024 strategic partnership with Cochlear to co-develop integrated neural interface devices including advanced depth electrode configurations, alongside earlier acquisitions of neuromodulation intellectual property from Neurotek Medical in 2016 and Medi-Line in 2017 to bolster electrode design and OEM manufacturing capabilities.